Summit Therapeutics Delists In London As Focus Shifts To US
Summit Therapeutics Delists In London As Focus Shifts To US
Read moreWed, 03rd Jul 2013 09:16
Summit Therapeutics Delists In London As Focus Shifts To US
Read moreSummit Therapeutics Chief Operating & Medical Officer Roblin Resigns
Read moreSummit Gets More Funding For C. Difficile Infection Treatment
Read moreSummit Therapeutics Shuffles Board After Raising USD50 Million
Read more(Sharecast News) - Antibiotic innovation company Summit Therapeutics raised $50.0m on Tuesday by way of a subscription and placing of new ordinary shares and warrants.
Read moreSummit Therapeutics Reports Decrease In Revenue In Third Quarter
Read moreSummit Therapeutics Plans Wholesale Changes As It Raises Cash
Read more(Sharecast News) - Antibiotic innovation company Summit Therapeutics announced a proposed fundraising of about $50m through a subscription and placing of new ordinary shares and warrants to existing investors on Friday, which would be subject to certain shareholder approvals being obtained and certain customary closing conditions being satisfied.
Read moreSummit Therapeutics Sinks To Interim Loss On Ezutromid Discontinuation
Read moreSummit Therapeutics Posts Explanation For Ridinilazole Trial In C Diff
Read moreSummit Therapeutics Reports Positive Ridinilazole Trial Results
Read more(Alliance News) - Summit Therapeutics PLC on Wednesday highlighted the potential of its preclinical new class antibiotic, SMT-571, to treat gonorrhoea, at the STI & HIV World Congress in said
Read more(Alliance News) - Summit Therapeutics on Wednesday said its loss narrowed in its financial first quarter due to an increase in other operating income and a reduction in operating which develops a
Read moreLONDON (Alliance News) - Summit Therapeutics PLC on Monday presented proof of concept data for its DDS-04 series of antibiotics targeting Enterobacteriaceae, a family of bacteria that cause severe
Read more(Sharecast News) - Antibiotic innovation firm Summit Therapeutics reported on in vivo proof-of-concept data for the DDS-04 series of new mechanism antibiotics targeting enterobacteriaceae on Monday, having presented them at the 29th European Congress of Clinical Microbiology and Infectious Diseases in Amsterdam.
Read more